352 related articles for article (PubMed ID: 30374965)
1. One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.
Svensson CK; Larsen JR; Vedtofte L; Jakobsen MSL; Jespersen HR; Jakobsen MI; Koyuncu K; Schjerning O; Nielsen J; Ekstrøm CT; Correll CU; Vilsbøll T; Fink-Jensen A
Acta Psychiatr Scand; 2019 Jan; 139(1):26-36. PubMed ID: 30374965
[TBL] [Abstract][Full Text] [Related]
2. Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.
Larsen JR; Vedtofte L; Jakobsen MSL; Jespersen HR; Jakobsen MI; Svensson CK; Koyuncu K; Schjerning O; Oturai PS; Kjaer A; Nielsen J; Holst JJ; Ekstrøm CT; Correll CU; Vilsbøll T; Fink-Jensen A
JAMA Psychiatry; 2017 Jul; 74(7):719-728. PubMed ID: 28601891
[TBL] [Abstract][Full Text] [Related]
3. Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial.
Larsen JR; Vedtofte L; Holst JJ; Oturai P; Kjær A; Correll CU; Vilsbøll T; Fink-Jensen A
BMJ Open; 2014 Mar; 4(3):e004227. PubMed ID: 24667381
[TBL] [Abstract][Full Text] [Related]
4. Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes - randomized controlled trial.
Maagensen H; Larsen JR; Jørgensen NR; Fink-Jensen A; Vilsbøll T
Psychiatry Res; 2021 Feb; 296():113670. PubMed ID: 33373806
[TBL] [Abstract][Full Text] [Related]
5. Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia.
Møller M; Fredholm S; Jensen ME; Wörtwein G; Larsen JR; Vilsbøll T; Ødum N; Fink-Jensen A
CNS Spectr; 2022 Jun; 27(3):347-354. PubMed ID: 33308348
[TBL] [Abstract][Full Text] [Related]
6. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
le Roux CW; Astrup A; Fujioka K; Greenway F; Lau DCW; Van Gaal L; Ortiz RV; Wilding JPH; Skjøth TV; Manning LS; Pi-Sunyer X;
Lancet; 2017 Apr; 389(10077):1399-1409. PubMed ID: 28237263
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis.
Siskind D; Hahn M; Correll CU; Fink-Jensen A; Russell AW; Bak N; Broberg BV; Larsen J; Ishøy PL; Vilsbøll T; Knop FK; Kisely S; Ebdrup BH
Diabetes Obes Metab; 2019 Feb; 21(2):293-302. PubMed ID: 30187620
[TBL] [Abstract][Full Text] [Related]
8. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes.
Mashayekhi M; Nian H; Mayfield D; Devin JK; Gamboa JL; Yu C; Silver HJ; Niswender K; Luther JM; Brown NJ
Diabetes; 2024 Jan; 73(1):38-50. PubMed ID: 37874653
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
[TBL] [Abstract][Full Text] [Related]
10. Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats.
Babic I; Gorak A; Engel M; Sellers D; Else P; Osborne AL; Pai N; Huang XF; Nealon J; Weston-Green K
J Psychopharmacol; 2018 May; 32(5):578-590. PubMed ID: 29493378
[TBL] [Abstract][Full Text] [Related]
11. Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight/obese persons with prediabetes.
Ariel D; Kim SH; Abbasi F; Lamendola CA; Liu A; Reaven GM
Nutr Metab Cardiovasc Dis; 2014 Dec; 24(12):1317-22. PubMed ID: 25280957
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis.
Overgaard RV; Petri KC; Jacobsen LV; Jensen CB
Clin Pharmacokinet; 2016 Nov; 55(11):1413-1422. PubMed ID: 27193270
[TBL] [Abstract][Full Text] [Related]
13. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
Rubino DM; Greenway FL; Khalid U; O'Neil PM; Rosenstock J; Sørrig R; Wadden TA; Wizert A; Garvey WT;
JAMA; 2022 Jan; 327(2):138-150. PubMed ID: 35015037
[TBL] [Abstract][Full Text] [Related]
14. Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study.
Chen CH; Huang MC; Kao CF; Lin SK; Kuo PH; Chiu CC; Lu ML
J Clin Psychiatry; 2013 May; 74(5):e424-30. PubMed ID: 23759461
[TBL] [Abstract][Full Text] [Related]
15. Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes.
Mensberg P; Nyby S; Jørgensen PG; Storgaard H; Jensen MT; Sivertsen J; Holst JJ; Kiens B; Richter EA; Knop FK; Vilsbøll T
Diabetes Obes Metab; 2017 Feb; 19(2):172-180. PubMed ID: 27717126
[TBL] [Abstract][Full Text] [Related]
16. Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: A 52-week randomized controlled clinical trial.
Foghsgaard S; Vedtofte L; Andersen ES; Bahne E; Andreasen C; Sørensen AL; Forman JL; Mathiesen ER; Svare JA; Clausen TD; Damm P; Holst JJ; Knop FK; Vilsbøll T
Diabetes Obes Metab; 2024 Jan; 26(1):201-214. PubMed ID: 37846555
[TBL] [Abstract][Full Text] [Related]
17. Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry).
Sass MR; Danielsen AA; Köhler-Forsberg O; Storgaard H; Knop FK; Nielsen MØ; Sjödin AM; Mors O; Correll CU; Ekstrøm C; Vinberg M; Nielsen J; Vilsbøll T; Fink-Jensen A
BMJ Open; 2023 Jan; 13(1):e068652. PubMed ID: 36720576
[TBL] [Abstract][Full Text] [Related]
18. Liraglutide 3.0 mg once daily for the treatment of overweight and obesity in patients hospitalised at a forensic psychiatric department: A 26-week open-label feasibility study.
Sass MR; Christensen AMB; Christensen ML; Gruber E; Nerdrum H; Pedersen LM; Resch M; Jørgensen TH; Ekstrøm CT; Nielsen J; Vilsbøll T; Fink-Jensen A
Acta Psychiatr Scand; 2024 Jul; 150(1):35-47. PubMed ID: 38631670
[TBL] [Abstract][Full Text] [Related]
19. Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial.
Tanaka K; Saisho Y; Manesso E; Tanaka M; Meguro S; Irie J; Sugiura H; Kawai T; Jinzaki M; Cobelli C; Itoh H;
Clin Drug Investig; 2015 Oct; 35(10):675-84. PubMed ID: 26369653
[TBL] [Abstract][Full Text] [Related]
20. Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.
Silver HJ; Olson D; Mayfield D; Wright P; Nian H; Mashayekhi M; Koethe JR; Niswender KD; Luther JM; Brown NJ
Diabetes Obes Metab; 2023 Aug; 25(8):2340-2350. PubMed ID: 37188932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
